Saovitinib's New Indication for the Treatment of Non-Small Cell Lung Cancer Accepted for Review in China

In a recent development, China's National Medical Products Administration (NMPA) has accepted the market application for a new indication of Saovitinib, a selective MET inhibitor, for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) patients with MET exon 14 skipping mutations. This exciting news comes from the pharmaceutical company, HUTCHMED. If approved, Saovitinib's label will expand to cover treatment for previously untreated patients, marking a significant advancement in the management of NSCLC.

Saovitinib has already received conditional approval in China for the treatment of NSCLC patients with MET exon 14 skipping mutations who have experienced disease progression after systemic therapy or are ineligible for chemotherapy. Collaborating with AstraZeneca, HUTCHMED launched Saovitinib under the brand name "Vizimpro®" in the market. Notably, approximately 2% to 3% of global NSCLC patients have been identified with MET exon 14 skipping mutations, making this new indication a promising therapeutic option for a specific patient population.

The clinical efficacy and safety data supporting Saovitinib's new indication were presented at the European Lung Cancer Conference (ELCC) in March 2024. The data revealed a median progression-free survival (PFS) of 13.7 months and overall survival (OS) data that is yet to be reached among previously untreated patients. These results provide compelling evidence for the use of Saovitinib as a targeted treatment option for both previously untreated and previously treated NSCLC patients with MET exon 14 skipping mutations.

In terms of safety, Saovitinib demonstrated a tolerable safety profile, with no new safety signals observed. The most common grade 3 or higher treatment-related adverse events (occurring in 5% or more of patients) included abnormal liver function, alanine transaminase elevation, aspartate transaminase elevation, peripheral edema, and gamma-glutamyl transferase elevation.

The acceptance of Saovitinib's new indication for the treatment of NSCLC patients with MET exon 14 skipping mutations by China's NMPA represents a significant milestone in the fight against lung cancer. If approved, this expanded indication will provide a much-needed treatment option for previously untreated patients, further addressing the unmet medical needs in the field of NSCLC. With ongoing advancements in targeted therapies, Saovitinib shows promise in improving outcomes for patients with specific genetic mutations, bringing hope for a brighter future in lung cancer treatment.